Joinn Laboratories (06127) achieved a net profit attributable to the parent company of 80.7061 million yuan in the first three quarters, turning losses into profits on a year-on-year basis.
Zhao Yan New Drugs (06127) announced that the group achieved operating income of 985 million yuan in the first three quarters of 2025,...
Joinn Laboratories (06127) announced that in the first three quarters of 2025, the group achieved operating income of 985 million yuan, a decrease of 26.23% year-on-year; net profit attributable to the parent company was 80.7061 million yuan, compared to a loss of 70.3071 million yuan in the same period last year; basic earnings per share was 0.11 yuan.
Related Articles

US Stock Market Move | Navan (NAVN.US) is listed on the US stock market, and its opening stock price has fallen.

US Stock Market Move | Q3 net loss expands, Roblox (RBLX.US) falls more than 10%

US Stock Market Move | Moderna (MRNA.US) rose over 9% after news of negotiations for acquisition with at least one major pharmaceutical company.
US Stock Market Move | Navan (NAVN.US) is listed on the US stock market, and its opening stock price has fallen.

US Stock Market Move | Q3 net loss expands, Roblox (RBLX.US) falls more than 10%

US Stock Market Move | Moderna (MRNA.US) rose over 9% after news of negotiations for acquisition with at least one major pharmaceutical company.

RECOMMEND

First in History: NVIDIA’s Market Capitalization Tops $5 Trillion
30/10/2025

Congressional Budget Office Estimates Government Shutdown Has Cost the U.S. Economy $18 Billion
30/10/2025

Wall Street on China’s Internet Sector: Distinct Investment Opportunities in AI and Gaming; Caution on E‑commerce
30/10/2025


